Cutaneous Squamous Cell Carcinoma Treatment Market Size & Trends 2021- expected to reach US$ 16,867.06 Million With CAGR of 7.2% by 2027, Finds Coherent Market Insights
SEATTLE, April 14, 2021, (PHARMIWEB) — Global Cutaneous Squamous Cell Carcinoma Treatment Market
Cutaneous squamous cell carcinoma is a type of non-melanoma skin cancer derived from cells within the epidermis that make keratin, the protein that makes up nails, hair, and skin. Most cutaneous squamous cell carcinoma are localized and easily treatable. According to the National Centre for Biotechnology Information, about 5% of experience local recurrence, 4% may develop nodal metastases, and about 2% die due to this disease.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4280
Increasing focus towards product development and ongoing trials are expected to drive growth of the global cutaneous squamous cell carcinoma treatment market during the forecast period. For instance, in May 2020, Regeneron Pharmaceuticals and Sanofi jointly initiated the clinical trial and announced the longer-term results for Libtayo (cemiplimab-rwlc), PD-1 inhibitor from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (cSCC).
Moreover, increasing prevalence of cutaneous squamous cell carcinoma is expected to augment the growth of the global cutaneous squamous cell carcinoma treatment market. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that squamous cell carcinoma is the second most common form of skin cancer in the U.S., followed by basal cell carcinoma. More than one million squamous cell carcinoma cases are diagnosed in the U.S. each year.
The emergence of COVID-19 (SARS-CoV-2) has affected financial status of several industry verticals worldwide. The private healthcare sector is one of the sectors, which has been majorly impacted by the global pandemic. Moreover, the pandemic has affected growth of various companies due to safety measures, such as nationwide lockdown, implemented by many governments worldwide.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4280
Higher cost, longer duration of the surgery, and the lack of standardization in guidelines is expected to hamper the global cutaneous squamous cell carcinoma treatment market growth.
- Cancer Institutes
- Ambulatory Surgical Centres
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
North America is expected to witness substantial growth to in the global cutaneous squamous cell carcinoma treatment market due to increasing approvals by regulatory bodies in the region. For instance, in June 2020, Merck & Co. received the U.S. Food and Drug Administration (FDA) approval for pembrolizumab (KEYTRUDA) for the treatment of recurrent or metastatic cutaneous squamous cell carcinoma (cSCC), which is not curable by surgery or radiation.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/cutaneous-squamous-cell-carcinoma-treatment-market-3543
Key players active in the global cutaneous squamous cell carcinoma treatment market are Sanofi S.A., Eli Lilly and Company, Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Amgen Inc., and Merck Sharp & Dohme.About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire